Develops radiopharmaceutical therapeutics for the treatment of cancer, combining precision targeting with potent therapeutic effects.
Perspective Therapeutics, Inc., based in Seattle, Washington, specializes in developing precision-targeted alpha therapies (TAT) for treating cancer patients with metastatic disease across various tumor types. The company is dedicated to discovering, designing, and advancing its initial program candidates, including VMT-a-NET and VMT01, both currently undergoing Phase 1/2a clinical trials.
VMT-a-NET is aimed at patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors who have not previously received peptide-targeted radiopharmaceutical therapy. Concurrently, VMT01 is being assessed in Phase 1/2a trials as a potential second-line treatment for patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Perspective Therapeutics has also established a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab for patients with histologically confirmed melanoma and positive MC1R imaging scans. Founded in 1998 as Isoray, Inc., the company rebranded to Perspective Therapeutics, Inc. in February 2022, solidifying its commitment to advancing innovative oncology therapies.